Immunizing with a peptide corresponding to a specific region of a protein antigen is a popular method to develop custom antibodies. With this strategy, you only need the amino acid sequence of a predicted/selected epitope within the protein antigen, avoiding homologous regions to minimize cross reactivity with other proteins. Antigenic peptides of 10-20 amino acids in length provide optimal epitope diversity while still offering superior specificity compared to immunizing with the full length protein sequence. The peptide is usually conjugated to a carrier protein such as KLH or BSA to enhance stimulation of an immune response. Antibodies are generated against the peptide sequence and the carrier protein. Therefore, the highly specific antibodies directed against the peptide are separated by affinity purification.
- Peptide epitopes represent antigen proteins
- Chemical synthesis yields defined epitopes
- Lower probability of cross-reactivity
- More flexibility in antigen selection
- Sequence diversity and PTMs can be addressed
- Easy to synthesize, cost-effective and stable
- Antigen design
- Production of antigen conjugates
- Titer determination
- Hybridoma screening
- Epitope mapping
- Antibody characterization
- Blocking peptides
- Sophisticated peptide microarrays improve and accelerate your hybridoma screening
- Antibody epitope mapping service using our proprietary PepStar™ peptide microarray technology
- Specificity testing of antibodies (including PTMs)
- SAR for antibody/peptide interactions
- Design and production of mimotopes and biosimilars
- Peptides as assay control
- Affinity Purification
"Expression of Programmed Death Ligand (PD-L1) in Different Tumors. Comparison of Several Current Available Antibody Clones and Antibody Profiling"
Kintsler et al., Annals of Diagnostic Pathology (2019)
"Der p 5 Allergen from House Dust Mite: First Epitope Mapping of Rabbit IgG Blocking Antibodies"
Lahiani et al., New Microbes and New Infections (2019)
"Envelope-Specific Epitope Recognition Patterns of HIV Vaccine-Induced IgG Antibodies are Linked to Immunogen Structure and Sequence"
Nadai et al, Front. Immunol (2019)
"Development of a Novel Fully-Human Anti-CD123 Antibody to Target Acute Myeloid Leukemia"
Baraniaket al, Leukemia Research (2019)
"Array-In-Well Epitope Mapping of Phage-Displayed Antibodies"
Lamminmäki et al., Epitope Mapping Protocols (2018)
"Analytical Performance of an Immunoassay to Measure Proenkephalin"
Donato et al, Clinical Biochemistry (2018)
"Comprehensive Characterization of Antibodies Directed towards Epigenetic Histone‐ Modifications"
Masch et al., Application Note (2015)
"Rapid Mimotope Optimization for Pharmacokinetic Analysis of the Novel Therapeutic Antibody IMAB362"
Daneschdar et al., Application Note (2014)
"A Modular Approach for Epitope Discovery and High‐Resolution Profiling of Humoral Immune Responses"
Pawlowski et al., Application Note (2013)
"BioTides™ as High Throughput Screening Tool for the Identification of Antibody Binding Sites"
Kühne et al., Application Note (2012)
Read More references
"The RV 144 HIV trial is considered as one of first successful HIV vaccine trials. It has become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT’s PepStar™ microarray technology has been very useful for the correlation of the clinical outcome with humoral immune responses. As have the cyclic peptides been from JPT to validate these findings!"
J. Currier, PhD (Walter Reed Army Institute, Rockville, Maryland, USA)
Read More references
Check our list of products,
click and go.